Drug abuse in the chronic pain patient

International Anesthesiology Clinics

Volumn 49, Issue 1, 2011, Pages 135-145

  Serban, Stelian ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CARISOPRODOL; CLONIDINE; CYCLOBENZAPRINE; GABAPENTIN; LAMOTRIGINE; LEVACETYLMETHADOL; METAXALONE; METHADONE; NORTRIPTYLINE; OPIATE; PARACETAMOL; PREGABALIN;

ACUPUNCTURE; AEROBIC EXERCISE; ARTICLE; CHRONIC PAIN; DRUG ABUSE; HUMAN; INCIDENCE; MASSAGE; MEDITATION; OPIATE ADDICTION; PHYSIOTHERAPY; PRIORITY JOURNAL; WITHDRAWAL SYNDROME; YOGA;

ANALGESICS, OPIOID; CHRONIC DISEASE; HUMANS; INCIDENCE; PAIN; SUBSTANCE-RELATED DISORDERS;

EID: 78751618281     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/AIA.0b013e31820aae93     Document Type: Article

References (30)

1. Hansen GR. The drug-seeking patient in the emergency room. Emerg Med Clin North Am. 2005;5:349-365.
2. US Department of Health and Human Services. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol TIP 40 [online]. Available from URL: http://www.naabt.org/ links/TIP-40-PDFpdf
3. Megarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006;25:79-85.
4. Yassen A, Olofsen E, van Dorp E, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the reversal of buprenorphine- induced respiratory depression by naloxone: a study in healthy volunteers. Clin Pharmacokinet. 2007;46:965-980.
5. Soyka M, Lieb M, Kagerer S, et al. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. J Clin Psychopharma-col. 2008;28:699-703.
6. Mintzer MZ, Correia CJ, Strain EC A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alcohol Depend. 2004;74:205-209.
7. Rapeli P, Fabritius C, Alho H, et al. Methadone versus buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol. 2007;7:5.
8. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanvir/ritonavir. Drug Alcohol Depend. 2007;91:269-278.
9. Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005; 100:1090-1100.
10. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formula of buprenorphine and naloxone. N Engl J Med. 2003; 349:949-958.
11. Kamien JB, Branstetter SA, Amass LA. Buprenorphine-naloxoneversus Methadone maintenance therapy: a randomized double-blind trial with opioid dependent patients. Heroin Addict Relat Clin Probl. 2008;10:5-18.
12. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N EnglJ Med. 2006;61:173-181.
13. Barnett PG. Comparison of costs and utilization among buprenorphine and Methadone patients. Addiction. 2009;104:982-992.
14. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007;129:235-255.
15. Polatin PB, Kinney RK, Gatchel RJ, et al. Psychiatric illness and chronic low back pain: the mind and the spine\which goes first? Spine. 1993;18:66-71.
16. Manchikanti L, Pampati V, Damron KS, et al. Prevalence of opioid abuse in interventional pain medicine practice settings: a randomized clinical evaluation. Pain Physician. 2001;4:358-365.
17. Toth JJ, Ulin MT, Kohl A. Commonly used muscle relaxant therapies for acute low back pain. Clin Therap. 2004;26:1355-1367.
18. Passik SD, Messina J, Golsorkhi A. Aberrant drug behavior in patients taking chronic opioid treatment. J Pain Symptom Manage. 2010;8:467-483.
19. Porter J, Jick H, Eriks M. Addiction in patients treated with narcotics. N Engl J Med. 1980;302:123.
20. Kanner JM, Foley K, Portenoy M. Patterns of narcotic drug use in a cancer pain clinic. Ann NY Acad Sci. 1981;23:162-172.
21. Weissman DE, Haddox JD, Kanter T. Opioid pseudoaddiction. Pain. 1989;36: 363-366.
22. Morgan J, Puder K, Connoly T. Postoperative analgesia and pseudoaddiction\an observational study. Pain. 1989;37:175-180.
23. Ziegler P, Benedetto A, Porter M. Substance Abuse: 2005;29:1945-1954.
24. Flor B, Fidrych H, Turk J. Efficacy of non-steroidal treatment in chronic pain patients. Pain. 1994;49:229-234.
25. Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in treatment of opioid dependence. Drugs. 2009;69:577-607.
26. Manchikanti L, Cash KA, Damron KS, et al. Controlled substance abuse and illicit drug use in chronic pain patients: an evaluation of multiple variables. Pain Physician. 2006;9:215-225.
27. McQuay F, Caroll G, Jadad K. Anticonvulsants for treating chronic pain. Br J Med. 1995;311:1949-1956.
28. Fields H, Conrad M, Bett K. Pain modulation and the action of analgesic medications. Neurology. 1994;48:277-289.
29. Manchikanti L, Manchukonda R, Pampati V, et al. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short-acting (hydrocodone) or long-acting (methadone) opioids. Pain Physician. 2005;8:257-261.
30. Adams LL, Gatchel RJ, Robinson RC, et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004;27:440-459.